Nature Biotech's five questions with Elham Azizi on interpretable ML for precision oncology
elhamazizi · x · 2026-09-03
Nature Biotechnology publishes a career-feature Q&A with multidisciplinary biomedical engineer Elham Azizi, who aims to bridge data-driven discovery and mechanistic understanding, advancing precision oncology through interpretable, biologically grounded machine learning and AI. Full text is behind a paywall.
Related event: Nature Biotechnology Interviews Azizi on Explainable AI in Cancer Research(2 posts)→
More from Research
- CBAI opens Fall AI Safety fellowship: $15k stipend, 10 weeks in Boston — benno_krojer · 2026-09-03
- What 12 million empirical research results can teach us — RexDouglass · 2026-09-03
- GamowLabs to launch RareBench challenge: can you tell synthetic genomes from real ones? — danielmckinn0n · 2026-09-03
- NEJM: Single-Dose In-Vivo B-Cell Depletion Helps All 16 Refractory Autoimmune Patients — EricTopol · 2026-09-03
- Multi-Teacher On-Policy Distillation emerges as 2026 post-training paradigm used in frontier models — cwolferesearch · 2026-09-03
- Protein folding models have always used recycling — effectively recurrent depth with stop grad — amyxlu · 2026-09-03